Collective Intelligence

The first interactive platform that brings together innovation players around common interest.

Fighting Asthma & COPD by reducing inhalers’ carbon footprint

Thanks to the Montreal Protocol, the ozone layer is projected to recover fully by 2066. By then, Ozone depletion will have caused tens of millions of excess skin cancers. A similar challenge is to reduce the carbon footprint of #HFCs used as substitutes for CFCs, in inhalers for asthma and COPD.

Our comment :

HFC phasedown is projected to deliver 0.3 to 0.5 degrees of climate benefit by 2100 but such a challenge requires time and both environmental and Industrial leadership to build a new sustainable value chain for the metered-dose inhalers manufacturing industry.
Olivia Uguen, One health and ESG strategies expert
ClosePlease login
ClosePlease login
ClosePlease login

Fighting Asthma & COPD by reducing inhalers’ carbon footprint

Thanks to the Montreal Protocol, the ozone layer is projected to recover fully by 2066. By then, Ozone depletion will have caused tens of millions of excess skin cancers. A similar challenge is to reduce the carbon footprint of #HFCs used as substitutes for CFCs, in inhalers for asthma and COPD.

BLUMORPHO comment :

HFC phasedown is projected to deliver 0.3 to 0.5 degrees of climate benefit by 2100 but such a challenge requires time and both environmental and Industrial leadership to build a new sustainable value chain for the metered-dose inhalers manufacturing industry.
Olivia Uguen, One health and ESG strategies expert
ClosePlease login
ClosePlease login
ClosePlease login

Fighting Asthma & COPD by reducing inhalers’ carbon footprint

Thanks to the Montreal Protocol, the ozone layer is projected to recover fully by 2066. By then, Ozone depletion will have caused tens of millions of excess skin cancers. A similar challenge is to reduce the carbon footprint of #HFCs used as substitutes for CFCs, in inhalers for asthma and COPD.

BLUMORPHO comment :

HFC phasedown is projected to deliver 0.3 to 0.5 degrees of climate benefit by 2100 but such a challenge requires time and both environmental and Industrial leadership to build a new sustainable value chain for the metered-dose inhalers manufacturing industry.
Olivia Uguen, One health and ESG strategies expert
ClosePlease login
ClosePlease login
ClosePlease login
ClosePlease login
ClosePlease login
ClosePlease login

Our previous articles

ClosePlease login